Development of N,N-Dimethylglycine-Amantadine for Adjunctive Dopaminergic Application: Synthesis, Structure and Biological Activity

N-methyl-D-aspartate (NMDA) receptor blockade can improve L-DOPA (l-3,4-dihydroxyphenylalanine)-induced dyskinesias in Parkinson’s disease (PD) patients. Amantadine is a well-tolerated and effective antiparkinsonian agent, recently found to possess NMDA antagonistic properties. Oxidative damage may contribute dopaminergic (DAergic) neurodegeneration the substantia nigra of patients with PD. N,N-dimethylglycine (DMG) (also known as vitamin B15 or pangamic acid) acts an antioxidant, extending lifespan animal cells through protection from oxidation. In this study, we synthesized tested vivo newly obtained compound N,N-dimethylglycine-amantadine (DMG-Am) for activity. MPTP (1-methyl-4–phenyl-1, 2, 3, 6-tetrahydropyridine) widely used neurotoxin induce experimental model which mimics Parkinson disease-like symptoms. The neuroprotective capacity new amantadine derivative DMG-Am was evaluated by its potential ameliorate neuromuscular coordination behavioral changes worsened toxin. Our results showed that applied 12 consecutive days, 5 days simultaneously 7 after MPTP, restored motor memory performance animals control level, indication beneficial protective effect compound. summary, our reveal promising agent.